RU2001124840A - ANTITUMER ANTISEMIC SEQUENCES AIMED AT COMPONENTS R1 AND R2 OF RIB NUCLEOTID REDUCASE - Google Patents

ANTITUMER ANTISEMIC SEQUENCES AIMED AT COMPONENTS R1 AND R2 OF RIB NUCLEOTID REDUCASE

Info

Publication number
RU2001124840A
RU2001124840A RU2001124840/15A RU2001124840A RU2001124840A RU 2001124840 A RU2001124840 A RU 2001124840A RU 2001124840/15 A RU2001124840/15 A RU 2001124840/15A RU 2001124840 A RU2001124840 A RU 2001124840A RU 2001124840 A RU2001124840 A RU 2001124840A
Authority
RU
Russia
Prior art keywords
antisense oligonucleotide
mammal
tumor cells
oligonucleotide according
sequence
Prior art date
Application number
RU2001124840/15A
Other languages
Russian (ru)
Inventor
Джим А. РАЙТ (CA)
Джим А. РАЙТ
Эйпинг Х. ЯНГ (CA)
Эйпинг Х. ЯНГ
Original Assignee
Дженесенс Текнолоджиз Инк. (Ca)
Дженесенс Текнолоджиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженесенс Текнолоджиз Инк. (Ca), Дженесенс Текнолоджиз Инк. filed Critical Дженесенс Текнолоджиз Инк. (Ca)
Publication of RU2001124840A publication Critical patent/RU2001124840A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

1. Антисмысловой олигонуклеотид из менее чем примерно 50 нуклеотидов, включающий последовательность AS-I-618-20 [SEQ ID NO 176].1. An antisense oligonucleotide of less than about 50 nucleotides, comprising the sequence AS-I-618-20 [SEQ ID NO 176]. 2. Антисмысловой олигонуклеотид по п. 1, проявляющий сниженную димеризацию и сниженные автокомплементарные взаимодействия.2. The antisense oligonucleotide according to claim 1, exhibiting reduced dimerization and reduced auto-complementary interactions. 3. Антисмысловой олигонуклеотид по п. 1 для подавления онкогенности опухолевых клеток у млекопитающего.3. The antisense oligonucleotide according to claim 1 for suppressing the oncogenicity of tumor cells in a mammal. 4. Антисмысловой олигонуклеотид по п. 1 для подавления онкогенности опухолевых клеток, резистентных к химиотерапевтическому лекарственному средству, у млекопитающего.4. The antisense oligonucleotide according to claim 1 for suppressing the oncogenicity of tumor cells resistant to a chemotherapeutic drug in a mammal. 5. Антисмысловой олигонуклеотид по п. 1 для повышения чувствительности опухолевых клеток к химиотерапевтическому лекарственному средству у млекопитающего.5. The antisense oligonucleotide according to claim 1 for increasing the sensitivity of tumor cells to a chemotherapeutic drug in a mammal. 6. Антисмысловой олигонуклеотид по п. 1 для подавления метастазирования опухолевых клеток у млекопитающего.6. The antisense oligonucleotide according to claim 1 for suppressing metastasis of tumor cells in a mammal. 7. Фармацевтическая композиция, включающая антисмысловой олигонуклеотид по любому из пп. 1-6 и фармацевтически приемлемый носитель или растворитель.7. A pharmaceutical composition comprising the antisense oligonucleotide according to any one of paragraphs. 1-6 and a pharmaceutically acceptable carrier or solvent. 8. Выделенная ДНК с последовательностью, включающей участок инициации транскрипции и последовательность, кодирующую антисмысловой олигонуклеотид из менее чем примерно 50 нуклеотидов, включающий последовательность AS-I-618-20 [SEQ ID NO 176].8. Isolated DNA with a sequence including a transcription initiation site and a sequence encoding an antisense oligonucleotide of less than about 50 nucleotides, including the sequence AS-I-618-20 [SEQ ID NO 176]. 9. Применение антисмыслового олигонуклеотида по п. 1 для подавления роста опухолевых клеток у млекопитающего.9. The use of the antisense oligonucleotide according to claim 1 for inhibiting the growth of tumor cells in a mammal. 10. Применение фармацевтической композиции по п. 7 для подавления роста опухолевых клеток у млекопитающего.10. The use of the pharmaceutical composition according to claim 7 for inhibiting the growth of tumor cells in a mammal. 11. Применение ДНК по п. 8 для подавления роста опухолевых клеток у млекопитающего.11. The use of DNA according to claim 8 for inhibiting the growth of tumor cells in a mammal. 12. Применение антисмыслового олигонуклеотида по любому из пп. 1-6 для производства лекарственного средства.12. The use of the antisense oligonucleotide according to any one of paragraphs. 1-6 for the manufacture of a medicinal product. 13. Применение ДНК по п. 8 для производства лекарственного средства.13. The use of DNA according to claim 8 for the manufacture of a medicinal product.
RU2001124840/15A 1999-02-11 2000-02-09 ANTITUMER ANTISEMIC SEQUENCES AIMED AT COMPONENTS R1 AND R2 OF RIB NUCLEOTID REDUCASE RU2001124840A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/249,730 US6121000A (en) 1999-02-11 1999-02-11 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US09/249,730 1999-02-11

Publications (1)

Publication Number Publication Date
RU2001124840A true RU2001124840A (en) 2004-03-27

Family

ID=22944744

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001124840/15A RU2001124840A (en) 1999-02-11 2000-02-09 ANTITUMER ANTISEMIC SEQUENCES AIMED AT COMPONENTS R1 AND R2 OF RIB NUCLEOTID REDUCASE

Country Status (17)

Country Link
US (1) US6121000A (en)
EP (1) EP1153128B8 (en)
JP (1) JP4424857B2 (en)
KR (1) KR20020013501A (en)
CN (1) CN1345373A (en)
AR (1) AR022583A1 (en)
AT (1) ATE309346T1 (en)
AU (1) AU780455B2 (en)
BR (1) BR0008788A (en)
CA (1) CA2366487A1 (en)
DE (1) DE60023845T2 (en)
ES (1) ES2259602T3 (en)
IL (1) IL144727A0 (en)
MX (1) MXPA01008137A (en)
NZ (1) NZ514090A (en)
RU (1) RU2001124840A (en)
WO (1) WO2000047733A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
WO2003087367A2 (en) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1597365B1 (en) * 2003-02-10 2013-10-09 Lorus Therapeutics Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2522730A1 (en) * 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2
CN1302936C (en) * 2003-05-02 2007-03-07 精工爱普生株式会社 Printer
EP1636363A1 (en) * 2003-05-21 2006-03-22 GeneSense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CA2553211A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
WO2005115405A1 (en) * 2004-04-28 2005-12-08 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
CA2577036A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
JP2009540011A (en) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． Compositions and methods for siRNA inhibition of angiogenesis
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
CA2745832A1 (en) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
DE102019000490A1 (en) * 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Use of oligonucleotides for the treatment of tumors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5766855A (en) * 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators
EP0917569B1 (en) * 1996-08-02 2005-11-09 GeneSense Technologies Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Also Published As

Publication number Publication date
IL144727A0 (en) 2002-06-30
CA2366487A1 (en) 2000-08-17
BR0008788A (en) 2001-11-06
EP1153128B8 (en) 2006-01-18
CN1345373A (en) 2002-04-17
WO2000047733A9 (en) 2001-03-15
AR022583A1 (en) 2002-09-04
DE60023845D1 (en) 2005-12-15
DE60023845T2 (en) 2006-08-10
MXPA01008137A (en) 2004-08-12
ATE309346T1 (en) 2005-11-15
NZ514090A (en) 2005-01-28
ES2259602T3 (en) 2006-10-16
KR20020013501A (en) 2002-02-20
US6121000A (en) 2000-09-19
AU780455B2 (en) 2005-03-24
AU2529200A (en) 2000-08-29
JP4424857B2 (en) 2010-03-03
WO2000047733A1 (en) 2000-08-17
EP1153128B1 (en) 2005-11-09
EP1153128A1 (en) 2001-11-14
JP2003500006A (en) 2003-01-07

Similar Documents

Publication Publication Date Title
RU2001124840A (en) ANTITUMER ANTISEMIC SEQUENCES AIMED AT COMPONENTS R1 AND R2 OF RIB NUCLEOTID REDUCASE
US7846907B2 (en) Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene
US7595304B2 (en) Polymeric oligonucleotide prodrugs
US11840688B2 (en) Compositions and methods for inhibiting gene expression of Hif2alpha
JP2006500958A5 (en)
WO1993012129A1 (en) Peptide nucleic acids and their effect on genetic material
Welch et al. Expression of ribozymes in gene transfer systems to modulate target RNA levels
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
HUP0103465A2 (en) Short oligonucleotides for the inhibition of vegf expression
HK1047437A1 (en) Gonadotropin releasing hormone receptor antagonists and their related methods of use.
JP2006503904A5 (en)
WO1997020924A1 (en) A class of oligonucleotides, therapeutically useful as antitumoural agents
PL364917A1 (en) T cell receptor vbeta-dbeta-jbeta sequence and methods for its detection
HUP0004877A2 (en) Novel nucleotid sequences coding for the sdha, sdhb and sdhc genes
Cohen Informational drugs: a new concept in pharmacology
WO2000027858A1 (en) Antisense oligonucleotides which inhibit telomerase's activity and their uses
HUP0200192A3 (en) Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction, their use in preparation of medicaments, medicaments and process for their preparation
CA2304313A1 (en) Composition and method for enhancing paracellular transport across cell layers
WO2002006318A3 (en) Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
RU2000122677A (en) OLIGONUCLEOTIDE SEQUENCES COMPLETE TO THE THIOREDOXINE OR THIOREDOXINE REDUCTASE GENES AND USING THEM FOR MODULATION OF CELL GROWTH
JPH11285391A (en) Anti-hiv medicine
RU2001116558A (en) NUCLEIC ACID CARRIERS AND PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY
WO2022256351A1 (en) Asymmetric short duplex dna as a novel gene silencing technology and use thereof
JP2021511022A (en) Oligonucleotides for regulating PIAS4 expression
WO2019030313A2 (en) Oligonucleotides for modulating ube3c expression